The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

The U.S. government will pay drugmakers Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine, the companies announced Friday.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Sanofi said May 17 it will soon launch a late-stage trial for the COVID-19 vaccine it is developing with GlaxoSmithKline after the vaccine produced a strong immune response in phase 2 trial ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

French drugmaker Sanofi SASY.PA is developing a protein-based COVID-19 vaccine employing the same approach it uses for its Flublok seasonal flu vaccine.

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s ...

Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.